首页> 外文期刊>The journal of clinical investigation >Inhibition of hyaluronan synthesis restores immune tolerance during autoimmune insulitis
【24h】

Inhibition of hyaluronan synthesis restores immune tolerance during autoimmune insulitis

机译:抑制乙酰透明质酸合成可恢复自身免疫性胰岛炎期间的免疫耐受

获取原文
获取外文期刊封面目录资料

摘要

We recently reported that abundant deposits of the extracellular matrix polysaccharide hyaluronan (HA) are characteristic of autoimmune insulitis in patients with type 1 diabetes (T1D), but the relevance of these deposits to disease was unclear. Here, we have demonstrated that HA is critical for the pathogenesis of autoimmune diabetes. Using the DO11.10xRIPmOVA mouse model of T1D, we determined that HA deposits are temporally and anatomically associated with the development of insulitis. Moreover, treatment with an inhibitor of HA synthesis, 4-methylumbelliferone (4-MU), halted progression to diabetes even after the onset of insulitis. Similar effects were seen in the NOD mouse model, and in these mice, 1 week of treatment was sufficient to prevent subsequent diabetes. 4-MU reduced HA accumulation, constrained effector T cells to nondestructive insulitis, and increased numbers of intraislet FOXP3~(+) Tregs. Consistent with the observed effects of 4-MU treatment, Treg differentiation was inhibited by HA and anti-CD44 antibodies and rescued by 4-MU in an ERK1/2-dependent manner. These data may explain how peripheral immune tolerance is impaired in tissues under autoimmune attack, including islets in T1D. We propose that 4-MU, already an approved drug used to treat biliary spasm, could be repurposed to prevent, and possibly treat, T1D in at-risk individuals.
机译:我们最近报道,细胞外基质多糖透明质酸(HA)的大量沉积是1型糖尿病(T1D)患者自身免疫性岛炎的特征,但这些沉积物与疾病的相关性尚不清楚。在这里,我们已经证明HA对自身免疫性糖尿病的发病机制至关重要。使用T1D的DO11.10xRIPmOVA小鼠模型,我们确定HA沉积物在时间和解剖上与胰岛炎的发展相关。此外,用HA合成抑制剂4-甲基伞形酮(4-MU)进行治疗,即使在胰岛炎发作后也可以阻止糖尿病的发展。在NOD小鼠模型中观察到了相似的效果,在这些小鼠中,治疗1周足以预防随后的糖尿病。 4-MU减少了HA的积聚,将效应T细胞限制在非破坏性胰岛炎中,并增加了胰岛内FOXP3〜(+)Tregs的数量。与观察到的4-MU治疗效果一致,Treg分化被HA和抗CD44抗体抑制,并被4-MU以ERK1 / 2依赖性方式挽救。这些数据可以解释在自身免疫攻击下组织(包括T1D中的胰岛)如何降低外周免疫耐受性。我们建议将4-MU(一种已经被批准用于治疗胆道痉挛的药物)重新用于预防和可能治疗高危人群的T1D。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号